This paper is a continuation of our previous work on an HIV-1 therapy model of fighting a virus with another virus [Jiang et al., 2009] . The work in [Jiang et al., 2009 ] investigated cascading bifurcations between equilibrium solutions, as well as Hopf bifurcation from a double-infected equilibrium solution. In this paper, we propose a modification of the model in [Revilla & GarciaRamos, 2003; Jiang et al., 2009] by adding a constant η to the recombinant virus equation, which accounts for the treatment of constant injection of recombinants. We study the dynamics of the new model and find that η plays an important role in the therapy. Unlike the previous model without injection of recombinant, which has three equilibrium solutions, this new model can only allow two biologically meaningful equilibrium solutions.
Introduction
More than twenty years after its discovery in early 1980s, the acquired immunodeficiency syndrome (AIDS) still remains one of the main causes of death of human beings. It is well known that AIDS is a result of the CD4 + T cells dropping below certain level, and the population of CD4 + T cells is closely related to the HIV virus load within the host. Naturally, controlling the virus load has been the main goal of all therapies of AIDS. Currently there are two types of drugs for therapy of HIV infection: the protease inhibitors and the reverse transcriptase inhibitors. Recent progress in genetic engineering has offered a potentially alternative therapy: modification of a viral genome can produce recombinants capable of attaching to the HIV infected cells and hence, reducing the replication rate of HIV virus. The idea of this method is similar to that of using P. Yu & X. Zou lytic bacteriophages to cure the human bacterial infections which has been used since the early 20th century, mainly in Eastern Europe and the former Soviet Union (see, e.g. [Slopek et al., 1987; Carlton, 1999; Sulakvelidze et al., 2001] ). Indeed, this method has been used to modify rhabdovirus, including the rabies and the vesicular stomatities, making them capable of infecting and killing cells previously attacked by HIV-1. For details, see, e.g. [Mebatsion et al., 1997; Nolan, 1997; Schnell et al., 1997; Wagner & Hewlett, 1999] .
To examine the efficacy of this approach of fighting a virus with a genetically modified virus, Revilla and Garcia-Ramos [2003] proposed a mathematical model which is a result of incorporating two more variables -the density w of the recombinant (genetically modified) virus and the density z of doubly-infected cells (by the wild HIV virus and the recombinants), into the standard and classic differential equation model for HIV infection (see, e.g. [Nowak & May, 2000] 
Here x(t), y(t) and v(t) are the densities of uninfected CD4 + T cells, infected CD4 + T cells and the free HIV virus respectively at time t. In this model, a mass action infection mechanism is adopted with an infection rate constant β. It is also assumed that the healthy cell is produced at a constant rate λ and die at a constant rate d, the infected cells die at rate a, the virions are cleared (by immune system) at rate p, and each infected cell produces and release new virus at rate k. Based on the fact that the engineered virus only codifies the coreceptor pair CD4 and CXCR4 of the host cell membrane and bind specifically to the protein complex gp120/41 of HIV-1 expressed on the surface of infected cells (see [Schnell et al., 1997] ), Revilla and Garcia-Ramos 
The model (2) assumes that the recombinants are only injected initially and there will be no subsequent injections. However, as in other therapies, subsequent treatments (injection in this context) may enhance the efficacy of the therapy. In this paper, we consider a simple injection mechanism, that is, a constant injection rate η, and explore the consequence of such a treatment. Adoption of such a constant injection rate treatment adds the term η to the last equation in (2) 
We will investigate how the injection rate η, together with other parameters, affects the dynamics of the model. For convenience of analysis, we first simplify system (3) by the following rescalings:
where ν = (λkβ) 1/3 , µ 1 = µ 2 = µ 3 = ν 2 kβ ,
By the above, system (3) 
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Note that in the new system (7), we still use the same notations for the scaled state variables and parameters as those in (3). In order to compare the dynamics of the new model system (7) with η = 0 to that of the model with η = 0 (i.e. a system equivalent to (2) which has been previously studied in [Jiang et al., 2009] ), we summarize the results obtained in [Jiang et al., 2009] as below.
Let
Then, we have the following conclusions on the dynamics of (7) with η = 0:
(i) when R 0 < 1, the infection-free equilibrium E 0 = (1/d, 0, 0, 0, 0) is globally asymptotically stable; (ii) when R 0 > 1, E 0 becomes unstable and there occurs the single-infection equilibrium
(iii) when R 0 ∈ (1, R 1 ) , E s is globally asymptotically stable; (iv) when R 0 > R 1 , E s becomes unstable and there occurs the double-infection equilibrium
(v) there is a R 2 > R 1 such that E d is asymptotically stable when R 0 ∈ (R 1 , R h ); (vi) when R 0 is further increased in some appropriate ways to some critical value R h , E d loses its stability, giving rise to some stable periodic solution via Hopf bifurcation.
In the rest of this paper, we analyze (7) with η > 0. Our results show that appropriate injection rate can help eliminate the HIV virus in the sense that the HIV infection free equilibrium can be made globally asymptotically stable by choosing η > 0 sufficiently large. This is in contrast to the conclusion for the case with η = 0 in which, the recombinants do not help eliminate the HIV virus but only help reduce the HIV load in the long term sense. We also show that insufficient injection may still lead to the persistence of the HIV virus, with the recombinants also being persistent. In such a case, the model may allow periodic dynamics arising from Hopf bifurcation within certain range of the model parameters. Numerical simulations are also carried out, which are guided by the analytical results obtained, and in turn, support these results.
The remainder of the paper is organized as below. In Sec. 2, we confirm that the model (7) is well-posed by showing non-negativity of and boundedness of solutions corresponding to non-negative initial values, and consider the structure of equilibria for the model. In Sec. 3, we prove that there is a threshold value for R 0 , denoted by R η 1 such that when R 0 < R η 1 , the HIV free equilibrium is globally asymptotically stable; when R 0 > R η 1 , the HIV free equilibrium becomes unstable and there occurs an infection equilibrium. In Sec. 4, we study the stability of the HIV infection equilibrium, and in Sec. 5, we explore Hopf bifurcation from this infection equilibrium. Section 6 is devoted to numerical demonstrations of the theoretical results. Section 7 gives some conclusions and also offers some discussion.
Non-Negativeness and Boundedness of Solutions and Equilibria
Due to their biological meanings, the negative values of the state variables of system (7) are not allowed. This requires that all solutions should remain non-negative as long as the initial values are non-negative. Moreover, solutions should remain bounded. We confirm these below.
Theorem 1. When the initial values are nonnegative, the solutions of system (7) remain nonnegative for τ > 0. Moreover, they are bounded.
Proof. First, consider the first equation of (7), yielding the solution for x(τ ):
which clearly shows that x(τ ) > 0 for τ > 0, provided that x(0) ≥ 0. Next, consider the second and the fourth equations in (7) as a nonautonomous system for y P. Yu & X. Zou and v:
with x = x(t) > 0 being proved above. By Theorem 2.1, p. 81 in [Smith, 1995] , we know that a solution of (12) with y(0) ≥ 0 and v(0) ≥ 0 remains non-negative for all τ ≥ 0 in its maximal interval of existence. Applying the same argument to the subsystem consisting of the third and fifth equations in (7), we also obtain the non-negativity of z(t) and w(t). It remains to prove that non-negative solutions of (7) are all bounded. Let (x(τ ), y(τ ), z(τ ), v(τ ), w(τ )) be a non-negative solution and consider
Then, differentiating V along (7) yields
This shows that any solution starting from a nonnegative initial value must be bounded. By the continuation theory of ODEs, the boundedness of a solution also implies that it exists for τ ≥ 0.
The equilibrium solutions of (7) can be obtained by setting the vector field of (7) to zero, yielding
where
Thus, similar to the previous model without injection (i.e. η = 0), the new model (7) 
Stability of the HIV Free
Equilibrium E η 0
In this section, we consider the stability of the HIV free equilibrium E η 0 . Let
We have the following theorem. For the first step, we use the Jacobian matrix of (7), which is given by
Evaluating J (7) at E η 0 yields the following characteristic polynomial:
indicating that the equilibrium E η 0 is asymptotically stable if and only if
For the second step, we apply the Fluctuation Lemma (see, e.g. [Hirsch et al., 1985] ). To achieve this, for a continuous and bounded function
Then, by the Fluctuation Lemma, there exists a sequence τ n with τ n → ∞ as n → ∞ such that
Thus, it follows from the first equation of (7) that
which, as n → ∞, yields the following estimate:
By applying similar argument to the second, third and fourth equations of (7), we obtain respectively
On the other hand, again by the Fluctuation Lemma, there exists a sequence s n with s n → ∞ as n → ∞ such that
Substituting s = s n into the fifth equation of (7) and letting n → ∞ leads to
Combining (21)- (22) and (24)- (26), we then have (24)) and z ∞ = 0 (by (23)). Now by the relations:
we conclude that as τ → ∞,
Thus, with z(τ ) → 0 and v(τ ) → 0, the first and last equations of (7) become asymptotically autonomous equations with the following limit equations: 
If c − acdp − abq + bη ≤ 0, the right-hand side of the above inequality is obviously positive; while if c − acdp − abq + bη > 0, the absolute value of the right-hand side of the above inequality cannot be greater than that of the left-hand side of the inequality. Thus, in any case, we have
The proof is complete.
Stability of the HIV Infection Equilibrium E η d
In this section, we assume R 0 > R η 1 (equivalent to qZ + −η > 0) and study the stability of the HIV infection equilibrium E 
where 
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In the following, we show that there is an
is stable for R η 1 < R 0 < R 2 . To achieve this, we first need to show that when R 0 > R η 1 , there exist parameter values such that
where ∆ i 's are Hurwitz quantities, given by
A direct computation yields
For ∆ 3 and ∆ 4 , however, it is not easy to determine their signs for general R 0 . Thus, we use the property that ∆ 3 and ∆ 4 continuously depend on the parameters. At R 0 = R η 1 , using (16), (27) , (29) with a direct calculation leads to
Since ∆ 3 , ∆ 4 and ∆ 5 depend on R 0 continuously, we can conclude that there must exist an
. This together with ∆ 1 = a 1 > 0 and ∆ 2 > 0, leads to the following conclusion.
Theorem 3. There exists an R
2 > R η 1 such that when R 0 ∈ (R η 1 , R 2 ), the HIV infection equilibrium E η d is asymptotically stable.
Hopf Bifurcation Analysis
In the previous section, we have shown that when R 0 is increased to cross the critical point R Proof. First, note that when R 0 > R η 1 is further increased, ∆ 1 = a 1 , ∆ 2 and a 5 remain positive, but ∆ 3 and ∆ 4 may become negative. The type of bifurcations depends on whether ∆ 3 or ∆ 4 first crosses zero. We want to prove that if ∆ 3 and ∆ 4 can ever become negative as R 0 increases, then ∆ 4 must cross zero before ∆ 3 does.
First, assume ∆ 4 = 0 at R 0 = R 4 > R 2 (R 2 is given in Theorem 3). Then, from (29) we have 
Now multiplying the third equation in (29) by a 5 results in
Subtracting (33) from (32) we obtain
Note that a 5 > 0. Further, we can show that
This together with (34) shows that ∆ 3 > 0 when ∆ 4 = 0. Conversely, assume, for the sake of contradiction, that ∆ 3 will change sign no later than ∆ 4 does. Then there exists an R 3 > R 2 such that ∆ 3 > 0, ∆ 4 > 0 for R 0 ∈ (R 1 , R 3 ), and ∆ 3 = 0, ∆ 4 ≥ 0 at R 0 = R 3 . Thus, at R 0 = R 3 , it follows from (29) with ∆ 3 = 0 that
Hence, ∆ 4 becomes
leading to a contradiction to ∆ 4 ≥ 0 at R 0 = R 3 . This confirms that when ∆ 4 crosses zero, ∆ 3 must remain positive. The above discussion, together with the Hopf critical condition obtained for high-dimensional systems [Yu, 2005] 
and then obtain 
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where the leading coefficient of c 10 is
Since R 0 > R η 1 implies that 1 dp − η q is positive, the sign of c 10 is determined by the sign of f 5 (d). Indeed,
Therefore, further increasing R 0 to some value R η h > R 1 by decreasing d can cause change of signs of ∆ 4 from ∆ 4 > 0 to ∆ 4 < 0, leading to occurrence Hopf bifurcation (see [Yu, 2005] ) as long as a > 0 is taken sufficiently small and c > 0 is taken sufficiently large. For general model parameters, quantitatively determining the above "small" and/or "large" is very difficult (if not impossible). In the next section, we will numerically explore this problem by fixing some parameters, using the above analysis as a guide line.
Remark 1. The above analysis shows that if we choose the parameters such that [Jiang et al., 2009] , we have seen that there is a difference in the bifurcation path, as is shown below:
and System (7) with injection (η = 0) :
It should be noted that if we consider the stability of E η s purely from the mathematical view point, we can show that it is always unstable since the coefficient a 5 for the characteristic polynomial of E η s , given by
is negative for any positive parameter values due to Z − < 0.
Numerical Illustration
In this section, we present numerical examples and simulations to demonstrate the theoretical results obtained in the previous sections. We choose d as a bifurcation parameter, and apply normal form theorem to determine bifurcation and stability of limit cycles.
For a consistent comparison, we take the same parameter values used for the model without an 
Since this modified model is a new one and there are no results in the literature about how to choose the injection parameter η, we will consider several different values of η to see the trends of the system asymptotic dynamics and the effect of η. Based on the bifurcation parameter d, we have
The equilibrium solution:
is stable when 0 < R 0 < R where Z + is given in (41). We shall consider several values of η starting from η = 0.01. It should be noted that since we take a = 0.93, which is quite close to 1, and b = p = q which makes the constant term in (38) negative, there might not exist R η h for large values of η. So for such a set of parameter values given in (39), we need to choose small values of η. For large values of η, we need to choose small values of a. We will also present a couple of cases for small a but large η. For brevity, we shall only present a detailed analysis on the case of η = 0.01, and summarize the results for other cases.
When η = 0.01, with other parameter values given in (39), the equilibrium solution E η 0 is stable for 0 < R 0 < 1.192012288786482
and bifurcates into the equilibrium solution E The eigenvalues of this characteristic polynomial P d (ξ) include a pure imaginary pair and three negative real values: −0.1281736434, −6.7317310171, −11.2454829553, where i is the imaginary unit, i 2 = −1.
In order to obtain the approximate solution of the bifurcating family of limit cycles, we apply the normal form theory and program using computer algebra system Maple, developed by Yu [1998] , to analyze the Hopf bifurcation of system (7) 
). The general normal form can be written in polar coordinates as:
where ω 0 = 0.7981309053, v 0 , v 1 , τ 0 , τ 1 are constants, expressed in terms of the original system parameters; v 0 and v 1 are called focus values (or Lyapunov coefficients). v 0 and τ 0 can be found from linearization at the critical point R 0 = R η h , while v 1 and τ 1 must be determined by using nonlinear analysis. r and θ represent the amplitude and phase of periodic motion (limit cycle), respectively. When v 1 < 0 (v 1 > 0), the Hopf bifurcation is supercritical (subcritival), giving rise to stable (unstable) limit cycles, and the periodic solutions can be approximated in terms of the steady-state solution of (45).
Let 
into (7) yields
in which ; −6.0192671940x 1 x 2 + 2.5626799918x 1 x 3 − 6.6797733300x 1 x 4 − 0.2398542988x 1 x 5 − 8.5981550372x 2 x 3 + 1.2458878774x 2 x 4 + 3.4989615815x 2 x 5 − 11.2393705622x 3 x 4 − 0.2177247953x 3 x 5 + 3.6456518531x 4 x 5
Here · · · denotes the terms including higher-order powers of µ. Now, the Jacobian of system (47) 
The coefficients v 0 and τ 0 are given by Yu and Huseyin [1988] :
Applying the Maple program [Yu, 1998 ] to system (47) (setting µ = 0) results in
Therefore, the third-order normal form (47) is given by
The steady-state solutions of (50) 
The solution r = 0 actually denotes the equilibrium solution E η d . A simple linearization of the first equation of (50) indicates that r = 0(E η d ) is stable for µ < 0, as expected. When µ increases from negative to cross zero, a Hopf bifurcation occurs and the amplitude of bifurcating periodic solutions is given by the nonzero steady-state solution
Since v 1 < 0, the Hopf bifurcation is supercritical, i.e. the bifurcating limit cycles are stable and the amplitude is given by Eq. (52), and the frequency is determined from the following equation:
Now we give a comparison of the two systems, one without injection (η = 0) and one with injection η = 0.01, as follows: Recalling that d decreases as R 0 is increasing, we know that by adding the constant injection η, the equilibrium E η 0 has larger stability interval, and delay the occurrence of Hopf bifurcation. This confirms that the constant injection of recombinant helps to cure disease. To this end, we show some simulation results for the case η = 0.01, based on Eq. (7), obtained by using a fourth-order Runge-Kutta method. We take the parameter values given in Eq. (39) [Jiang et al., 2009] .
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The simulated time history and phase portraits for the above four cases are shown in Figs. 1-4 , respectively, where the initial condition is [Jiang et al., 2009] ).
For the last two cases, the simulated amplitudes of the limit cycles (see Figs. 3 and 4) are close to the predicted values, r = 0.2591 for Fig. 3 , and r = 0.3581 for Fig. 4 , showing a good agreement between the theoretical prediction and numerical simulation results, not only qualitatively, but also quantitatively. It can be seen from these two figures that a small change in µ can cause large variation of the amplitudes.
The period of motion, T = 2π ω (ω is given in Eq. (53)), decreases as µ increases. In other words, T decreases as d decreases. However, since µ is quite small, the change of the period due to µ is not significant [hardly to observe from Figs. 3(a) and 4(a)].
By using the above process, for the fixed parameter values given in (39), we can similarly consider bifurcation of limit cycles for different values η = 0.02, 0.04, 0.05, 0.1, etc. We have found that there does not always exist d η h at which a Hopf bifurcation occurs. This is because a = 0.93 is quite close to 1. In fact, for these fixed parameter values, η has a limit value η = 0.0412442708 for which all the Hurwitz conditions are satisfied even as d → 0 + . In other words, for such a case, the equilibrium solution E η d is always stable, and no Hopf bifurcation can occur.
We summarize the results for the cases: η = 0.02, η = 0.04 and η = 0.0412442708026295 below. The critical points d 
It should be pointed out that the above two normal forms are obtained from the two different critical points corresponding to the two different values of η = 0.02, 0.04, though both cases use d as a bifurcation parameter. Therefore, the estimate of the amplitude of the periodic motion (limit cycle) may not be consistent for comparison with respect to η, and so we cannot make a conclusion on the trend of the effectiveness of η. As a matter of fact, if taking µ = 0.0004, we obtain the amplitudes of the two limit cycles estimated from the above normal forms as 
We compare two cases: The numerical simulation results for the above two cases are shown in Figs. 6(a) and 6(b), respectively. These figures indeed show a good agreement with the theoretical predictions, confirming that increasing η does help to control the disease.
To this end, we consider a couple of cases for small a. Suppose a = 0.02, and other parameters are still the same as that given in (39). Again we treat η as bifurcation parameter and fix d = 0.02.
Then it can be shown that for these parameter values, η h = 0.3995538746. Then the normal form for this case is dr dτ = r(0.1996192042µ − 0.0624230311r 2 ), dθ dτ = 1.6338126963 + 0.0051686823µ The numerical simulation results for the above two cases are shown in Figs. 7(a) and 7(b) , respectively. These figures indeed show that large values of η decrease the amplitudes of motion, as expected. Thus, the injection is beneficial to cure the decease. However, due to large perturbation, the error between the theoretical prediction and numerical results is larger than that of small perturbations. This can be seen by comparing Figs. 6(a) and 6(b) (for smaller perturbation) with Figs. 7(a) and 7(b) (for larger perturbation). It may be noted that the phase portraits shown in Figs. 3-7 are projected on the x-y plane, indicating that increasing the value of η is indeed beneficial in controlling the Hopf bifurcation, reducing the amplitude of the motion with respect to the variables x and y. This is also true for the variables z and v. For the variable w, it is not so obvious if increasing η will also help to decrease the amplitude of w since η is a positive input for the rate of change w [see the fifth equation of (7)]. However, the time history of w for the last two cases [shown in Figs. 7(a) and 7(b)] actually indicates that an increase in η is also good for controlling the motion of w, as depicted in Figs. 8(a) and 8(b) . This is because changing the value of η mainly affect the equilibrium solution, but not the dynamical motion. In other words, for equilibrium solutions, increasing η can help to stabilize the equilibria, while for periodic motions, increasing η can decrease the amplitudes of motions. Hence, we can conclude that increasing η is beneficial in controlling the disease.
Conclusion and Discussion
In this paper, in order to study the consequence of the continuous constant injection of a genetically modified virus in the therapy of "fighting HIV virus with another virus", we incorporate a new term into the model considered in [Revilla & Garcia-Ramos, 2003; Jiang et al., 2009 ] to describe the interaction of the CD4 + T cells, the HIV virus and the recombinant virus. The added injection measurement (η) helps one understand the mechanism of therapy treatment and how to control the injection in controlling the disease. This new model includes the one in [Revilla & Garcia-Ramos, 2003; Jiang et al., 2009 ] as a special case. However, mathematically it has been shown that the dynamics of this model with η > 0 has a significant difference from that of the model with η = 0. For example, unlike the previous model in [Revilla & GarciaRamos, 2003; Jiang et al., 2009] which has three equilibrium solutions: infection-free equilibrium E 0 , single-infection equilibrium E s and double-infection equilibrium E d ; this new model only allows two equilibrium solutions: infection-free equilibrium E aq . An immediate biological implication is that, while the treatment without subsequent injection (η = 0) does not help at all eliminate the HIV virus completely, the treatment with a constant injection rate does. To see this, we first note that R 0 is independent of η. If R 0 > 1, then the HIV virus will remain persistent if η = 0, although the HIV load will be reduced by the introduction of the recombinants (see [Jiang et al., 2009] ).
But with η > 0, even if R 0 > 1, as long as η > aq(R 0 − 1), HIV virus will be eventually eliminated (Theorem 3).
When considering bifurcation to the doubleinfection equilibrium, we notice that R η 1 is usually smaller than R 1 , however the critical value R η h is usually much larger than R h , implying that E which shows that an increase in η greatly increases the Hopf critical value. Moreover, the numerical example with the normal form analysis and simulation, presented in Sec. 6, indicates that an increase in η is also beneficial in controlling the amplitudes of bifurcating periodic motions. In summary, the results obtained in this paper based on the modified HIV-1 model (7) clearly indicates that increasing η is beneficial for controlling/eliminating the HIV virus. We point out that the adoption of a constant injection rate is just for simplicity of analysis in this first attempt. In reality, other types of injection strategies may be more feasible. For example, impulsive injection strategy and periodic injection strategy are more reasonable injection mechanism. Of course, adopting such injection strategies will increase the difficulty level in analyzing the resulting model system.
